Erik Anders Kronström

Direttore operativo presso INFANT BACTERIAL THERAPEUTICS AB

Patrimonio netto: 106 222 $ in data 31/05/2024

57 anni

Health Technology

Consumer Services

Profilo

Erik Anders Kronström is currently the Chief Operating Officer at Infant Bacterial Therapeutics AB since 2018.
Previously, he worked as the Chief Executive Officer at Biosergen AS.
He holds an MBA from Warwick Business School and a graduate degree from the Royal Institute of Technology.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
INFANT BACTERIAL THERAPEUTICS AB CLASS B 0.09%	28/05/2024	11 194 ( 0.09% )	106 222 $	31/05/2024

Posizioni attive di Erik Anders Kronström

Società	Posizione	Inizio
INFANT BACTERIAL THERAPEUTICS AB	Direttore operativo	01/01/2018

Tutte le posizioni attive di Erik Anders Kronström

Precedenti posizioni note di Erik Anders Kronström

Società	Posizione	Fine
Biosergen AS Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.	Amministratore Delegato	-

Vedi nel dettaglio l'esperienza di Erik Anders Kronström

Formazione di Erik Anders Kronström

Royal Institute of Technology	Graduate Degree
Warwick Business School	Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Erik Anders Kronström

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
INFANT BACTERIAL THERAPEUTICS AB	Health Technology

Aziende private	1
Biosergen AS Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway.	Health Technology